Cannabidiol Medication Intervention Trial

This trial is testing whether cannabidiol (CBD), a non-psychoactive compound from cannabis, can reduce agitation in people with Alzheimer's disease and major neurocognitive disorder. Agitation (including restlessness, aggression, and irritability) is one of the most distressing symptoms of Alzheimer's. **You may be eligible if...** - You are 55 or older - You have been diagnosed with major neurocognitive disorder likely due to Alzheimer's disease (or Alzheimer's combined with vascular causes) - You have significant agitation that meets established clinical criteria, present at both the screening and baseline visits - You scored 24 or below on a standard cognitive test (sMMSE ≤24) - If you take cognitive medications (e.g., donepezil, memantine), your dose has been stable for at least 3 months - You have a primary caregiver who can attend study visits and participate alongside you **You may NOT be eligible if...** - Your agitation is not clinically significant - Your caregiver is unavailable or doesn't speak English well enough - You have severe medical or psychiatric conditions that may complicate participation Talk to your doctor to see if this trial is right for you.